Home
Conditions
Neoplasms, Plasma Cell

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,604 public trials 547 recruiting studies

Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Completed

A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma

NCT00915408

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: King's College Hospital NHS Foundation Trust London, United Kingdom

Royal Marsden NHS Foundation Trust London, United Kingdom

View Trial Details

Completed

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

NCT00060645

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations: Cancer Therapy and Research Center, University of Texas Health Center at San Antonio San Antonio, Texas, United States

View Trial Details

Completed

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

NCT00060632

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations: Not specified

View Trial Details

Completed

Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

NCT00217438

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations: Cedars-Sinai Medical Center Los Angeles, California, United States

University of Rochester Rochester, New York, United States

VA Puget Sound Health Care System Seattle, Washington, United States

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

NCT01085214

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Moffitt Cancer Center Tampa, Florida, United States

Emory University/Winship Cancer Institute Atlanta, Georgia, United States

University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States

Mark O Hatfield-Warren Grant Magnuson Clinical Center Bethesda, Maryland, United States

View Trial Details

Completed

Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia

NCT00566332

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +20 more
Locations: Hôpital La Pitié-Salpêtrière. 47-83 Bd de l'hôpital Paris, France

View Trial Details

Completed

Therapeutic Research in Multiple Myeloma

NCT00572338

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: University of Arkansas for Medical Sciences/MIRT Little Rock, Arkansas, United States

View Trial Details

Completed

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

NCT01658319

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +85 more
Locations: Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States

View Trial Details

Completed

Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant

NCT01959477

Conditions: Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, +202 more
Locations: Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States

View Trial Details

Completed

Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma

NCT02221479

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Investigational Site Number 392105 Kamogawa-Shi, Japan

Investigational Site Number 392103 Kyoto, Japan

Investigational Site Number 392102 Nagoya, Japan

Investigational Site Number 392104 Okayama, Japan

View Trial Details

Neoplasms, Plasma Cell

Neoplasms, Plasma Cell trial results

Related conditions